Cell Therapeutics' lymphoma drug, Pixuvri gets EU conditional marketing approval pharmabiz.com The EMA's Committee for Medicinal Products for Human Use (CHMP) has accepted PIX306, CTI's ongoing randomized controlled phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after 1 to 3 prior ... |
